Clinical Trial Update: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories [Phase 4]

View source ↗

Summary

Phase 4 study evaluating implementation strategies for delivering Apretude (cabotegravir) as HIV PrEP among Black cisgender and transgender women in the United …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 4 | Status: COMPLETED